Argos Therapeutics Rating Lowered to Neutral at Zacks (ARGS)
Argos Therapeutics (NASDAQ:ARGS) was downgraded by Zacks to a “neutral” rating in a research report issued on Wednesday. They currently have a $9.00 target price on the stock. Zacks‘s target price points to a potential upside of 2.86% from the company’s current price.
Argos Therapeutics (NASDAQ:ARGS) remained flat at $8.75 during trading on Wednesday. 29,311 shares of the company’s stock traded hands. Argos Therapeutics has a 1-year low of $5.611 and a 1-year high of $13.74. The stock has a 50-day moving average of $6.81 and a 200-day moving average of $8.32. The company’s market cap is $172.0 million.
Argos Therapeutics (NASDAQ:ARGS) last announced its earnings results on Wednesday, August 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.01. The company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.27 million. Analysts expect that Argos Therapeutics will post $-2.56 EPS for the current fiscal year.
Separately, analysts at Stifel Nicolaus initiated coverage on shares of Argos Therapeutics in a research note on Tuesday, August 19th. They set a “buy” rating and a $16.00 price target on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $15.40.
Argos Therapeutics Inc is a United States-based biopharmaceutical company. The company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis technology platform.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.